Search Results - "Bliesath, H"

A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation by Novick, J., Miner, P., Krause, R., Glebas, K., Bliesath, H., Ligozio, G., Rüegg, P., Lefkowitz, M.

“…Summary Background : Irritable bowel syndrome is a common functional gastrointestinal disorder which affects up to 20% of the population, with a predominance…”
Get full text

Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers by Bauer, M, Bliesath, H, Leuratti, C, Lackner, E, Dieterle, W, Müller, M, Brunner, M

“…Ralfinamide is an α-aminoamide derivative with ion channel blocking properties, acting both peripherally and centrally through different molecular targets…”
Get more information

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole by Hartmann, M, Theiss, U, Huber, R, Lühmann, R, Bliesath, H, Wurst, W, Lücker, P W

“…Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 enzyme system in man. Its effect on intragastric…”
Get more information

Pharmacokinetics of pantoprazole in man by Huber, R, Hartmann, M, Bliesath, H, Lühmann, R, Steinijans, V W, Zech, K

“…The proton pump inhibitor pantoprazole is a substituted benzimidazole sulphoxide for the treatment of acid-related gastrointestinal diseases such as reflux…”
Get more information

Pharmacokinetics of pantoprazole in man by Huber, R, Hartmann, M, Bliesath, H, Lühmann, R, Steinijans, V W, Zech, K

“…The proton pump inhibitor pantoprazole is a substituted benzimidazole sulphoxide for the treatment of acid-related gastrointestinal diseases such as reflux…”
Get more information

Lack of pharmacokinetic interaction of pantoprazole with diazepam in man by GUGLER, R., HARTMANN, M., RUDI, J., BROD, I., HUBER, R., STEINIJANS, V. W., BLIESATH, H., WURST, W., KLOTZ, U.

“…Pantoprazole, a substituted benzimidazole, is a potent and well tolerated inhibitor of the gastric H+,K+‐ATPase with a low potential to inhibit cytochrome…”
Get full text

Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin [see comments] by Duursema, L., Muller, FO, Schall, R., Middle, MV, Hundt, HK, Groenewoud, G., Steinijans, VW, Bliesath, H.

“…Twenty‐six healthy males took part in this double‐blind, randomised, placebo‐controlled, two‐period, cross‐over study. Pantoprazole (40 mg) (test) or placebo…”
Get full text

Lack of pantoprazole drug interactions in man: an updated review by Steinijans, V W, Huber, R, Hartmann, M, Zech, K, Bliesath, H, Wurst, W, Radtke, H W

“…This review summarizes the results of pharmacokinetic and pharmacodynamic drug interaction studies in man with pantoprazole, a new, selective proton pump…”
Get more information

Lack of pantoprazole drug interactions in man: an updated review by Steinijans, V W, Huber, R, Hartmann, M, Zech, K, Bliesath, H, Wurst, W, Radtke, H W

“…This review summarizes the results of pharmacokinetic and pharmacodynamic drug interaction studies in man with pantoprazole, a new, selective proton pump…”
Get more information

Pantoprazole does not interact with the pharmacokinetics of carbamazepine by Huber, R, Bliesath, H, Hartmann, M, Steinijans, V W, Koch, H, Mascher, H, Wurst, W

“…Pantoprazole is a H+/K+-ATPase inhibitor with a minimized potential of interaction with the cytochrome P450 system. Imidazole derivatives such as cimetidine…”
Get more information

Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers by Ullmann, U, Lehnfeld, R, Bliesath, H, Birkel, M, Gebbing, H, Gräve, M, Wolf, H

“…Imipramine is a tricyclic antidepressant drug with a considerable hepatic first-pass metabolism resulting in highly variable pharmacokinetic characteristics…”
Get more information

Pantoprazole lacks induction of CYP1A2 activity in man by Hartmann, M, Zech, K, Bliesath, H, Steinijans, V W, Koch, H, Wurst, W, Mascher, H

“…This drug-drug interaction study investigated the potential influence of the proton pump inhibitor pantoprazole on the CYP1A2 activity as assessed by urinary…”
Get more information

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man by EHRLICH, A, FUDER, H, LÜCKER, P. W, HARTMANN, M, WIECKHORST, G, TIMMER, W, HUBER, R, BIRKEL, M, BLIESATH, H, STEINIJANS, V. W, WURST, W

“…Pantoprazole is a selective proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 enzymes in man. Due to the clinical…”
Get full text

Lack of pharmacokinetic interaction between pantoprazole and diclofenac by Bliesath, H, Huber, R, Steinijans, V W, Koch, H J, Wurst, W, Mascher, H

“…The new H+/K+ ATPase inhibitor pantoprazole is extensively metabolized by the liver. As substituted benzimidazoles may potentially interact with the cytochrome…”
Get more information

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man by Hartmann, M, Huber, R, Bliesath, H, Steinijans, V W, Koch, H J, Wurst, W, Kunz, K

“…Substituted benzimidazole inhibitors of the gastric H+/K+ATPase may interact with the cytochrome P450 enzyme system and alter the pharmacokinetics of…”
Get more information

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man by Hartmann, M, Huber, R, Bliesath, H, Steinijans, V W, Koch, H J, Wurst, W, Kunz, K

“…Substituted benzimidazole inhibitors of the gastric H+/K+ATPase may interact with the cytochrome P450 enzyme system and alter the pharmacokinetics of…”
Get more information

Pantoprazole does not interact with nifedipine in man under steady-state conditions by Bliesath, H, Huber, R, Steinijans, V W, Koch, H J, Kunz, K, Wurst, W

“…The new H+/K+ -ATPase inhibitor pantoprazole is extensively metabolized by the liver. As substituted benzimidazoles can interact with the cytochrome P450…”
Get more information

No influence of pantoprazole on the pharmacokinetics of phenytoin by Middle, M V, Müller, F O, Schall, R, Groenewoud, G, Hundt, H K, Huber, R, Bliesath, H, Steinijans, V W

“…Twenty-three healthy, male volunteers completed this doubleblind, randomized, placebo controlled, 2-period crossover study to assess the influence of multiple…”
Get more information

Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers by Koch, H J, Hartmann, M, Bliesath, H, Huber, R, Steinijans, V W, Mascher, H, Wurst, W

“…The new H+/K+ ATPase inhibitor pantoprazole, a substituted benzimidazole, is metabolized by the hepatic cytochrome P450 enzymes 2C19 or 3A4 and subsequently…”
Get more information

Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration by Bliesath, H, Huber, R, Hartmann, M, Lühmann, R, Wurst, W

“…Pantoprazole is a specific inhibitor of the H+/K(+)-ATPase of the gastric parietal cell. The dose-dependency of a range of pantoprazole pharmacokinetic…”
Get more information